Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
ELUT
SELLElutia Inc. · Healthcare · United States · $51M · Avg Vol: $91K/d
COMPANY DESCRIPTION
Elutia Inc. develops and commercializes proprietary biologic drug-eluting matrices and regenerative medicine products. The company's competitive moat is secured by its proprietary CanGaroo envelope platform, which delivers targeted antibiotics to prevent surgical site infections. It is a specialized medical device player focused on the high-margin cardiovascular and reconstructive surgery markets.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 23.8M | 24.7M | 14.5M | 12.3M | -19.8% | 12.5M | 12.0M | 13.1M | 3.2% |
| EPS | -0.64 | -2.07 | -1.86 | 1.29 | — | -0.63 | -0.60 | -0.52 | — |
| Shares | 44.2M | 23.2M | 35.2M | 42.8M | -3.2% | 44.2M | — | — | — |
| Debt | 24.5M | 24.0M | 24.0M | 3.9M | -45.6% | 4.2M | — | — | — |
| Equity | -5.0M | -38.6M | -46.3M | 27.7M | — | — | — | — | — |
| Op CF | -21.4M | -21.8M | -22.7M | -44.8M | — | -43.8M | — | — | — |
| Inv CF | -0.5M | 14.2M | -0.5M | 78.6M | — | — | — | — | — |
| Fin CF | 8.5M | 9.8M | 17.1M | -10.6M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ELUT are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| ELUT | Elutia Inc.(you) | $51M | 23 | SELL |
| ECOR | electroCore, Inc. | $51M | 24 | SELL |
| ARAY | Accuray Incorporated | $53M | 18 | STRONG SELL |
| MDAI | Spectral AI, Inc. | $52M | 18 | STRONG SELL |
| LUNG | Pulmonx Corporation | $53M | 17 | STRONG SELL |
| COCH | Envoy Medical, Inc. | $51M | 14 | STRONG SELL |
| OM | Outset Medical, Inc. | $75M | 15 | STRONG SELL |
| LNSR | LENSAR, Inc. | $69M | 11 | STRONG SELL |
| AVH.AX | AVITA Medical, Inc. | $115M | 19 | STRONG SELL |
| MXCT | MaxCyte, Inc. | $116M | 28 | SELL |
Peer medians: ROE -25.6% · P/E 27.7x · Gross margin 50.5%